Research programme: CNS oligonucleotide therapeutics - BioMarin Pharmaceutical
Latest Information Update: 02 May 2024
At a glance
- Originator BioMarin Pharmaceutical
- Class Oligonucleotides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical CNS disorders
Most Recent Events
- 23 Apr 2024 Preclinical trials in CNS disorders in USA (Parenteral) before April 2024 (BioMarin Pharmaceutical pipeline, April 2024)